Skip to main content
Premium Trial:

Request an Annual Quote

David Kettner, Robert Zaugg, Nathan Tinker, Greg Simon, Lee Goldman, Jim Greaves, Chris McCleary, Vin Miles

Premium
The Wisconsin Alumni Research Foundation last week said that David Kettner, in-house counsel for WARF, will leave after March 30 to become chief intellectual property counsel for Virent Energy Systems, a Madison-based company developing carbon-neutral renewable energy products.
 
WARF said that Kettner will continue to work at WARF one or two days per week for a period of time after March 30. Kettner holds a law degree and BS in genetic and cellular biology from the University of Minnesota.
 

 
The Burnham Institute for Biomedical Research this week appointed Robert Zaugg to the position of vice president of business development, the institute said.
 
Zaugg will be responsible for all business development activities at Burnham, including technology licensing and establishing strategic alliances to support the institute’s scientists in La Jolla and Santa Barbara, Calif., and Orlando, Fla. Zaugg has worked as an independent consultant and has served as interim CEO of several California biotech companies, including DermAegis and Optime Therapeutics. He has also been general manager of GTS Proteomics; vice president of business development at Triton (now Berlex Biosciences); and assistant director of technology assessment at Sandoz (now Novartis). Zaugg earned his postdoc from the Massachusetts Institute of Technology, a PhD and MS from Northwestern University, and an MBA from New York University.
 

 
The New York Biotechnology Association last week announced that Nathan Tinker has been named executive director.
 
Tinker most recently was director of Antenna Group’s East coast office. He also formerly served as founder and executive vice president of the NanoBusiness Alliance, a trade association for the nanotechnology community; and as executive director of the Cancer Vaccine Consortium at the Sabin Vaccine Institute. He holds a PhD from Fordham University.
 
NYBA also said last week said that Greg Simon, president of FasterCures, and Lee Goldman, executive vice president for health and biomedical sciences at Columbia University, will be the featured speakers at NYBA’s 17th Annual Meeting on April 10 in New York.
 

 
ITI Life Sciences has appointed Jim Greaves to the post of director of marketing and communications, ITI said last week.
 
Greaves arrives at ITI from CXR Biosciences, where he served as director of business development.
 
Greaves formerly was director of European marketing for Invitrogen.
 

 
Baltimore’s Emerging Technology Center, a non-profit business incubator focused on growing early-stage technology and biotechnology companies, has selected Chris McCleary to join its board of directors.
 
McCleary is currently director of Blue Chip Venture, a Cincinnati-based venture capital firm. Blue Chip recently tapped McCleary to open an office in Maryland to expand its presence in the Mid-Atlantic region, Blue Chip said. Prior to Blue Chip, McCleary founded several companies including Digex, USinternetworking, and Evergreen.
 

 
Abingworth, a life sciences investment group, recently announced the appointment of Vin Miles as venture partner.
 
Miles, the former senior vice president of business development at Alnylam Pharmaceuticals, will be responsible for evaluating new investment opportunities and supporting portfolio companies on the East coast, Abingworth said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more